The latest price target for Tonix Pharmaceuticals (NASDAQ:TNXP) was reported by Alliance Global Partners on July 22, 2024. The analyst firm set a price target for $11.00 expecting TNXP to rise to within 12 months (a possible 7403.41% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Tonix Pharmaceuticals (NASDAQ:TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals maintained their buy rating.

There is no last upgrade for Tonix Pharmaceuticals

There is no last downgrade for Tonix Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.

While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a maintained with a price target of $6.00 to $11.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.15, which is out of the analyst’s predicted range.